SINGAPORE and NORTH BRUNSWICK, N.J., April 16, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (Nasdaq: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced that it has entered into a securities purchase agreement for a private investment in public equity financing that is expected to result in gross proceeds of approximately $150.0 million, before deducting placement agent fees and other private placement expenses..

新加坡和新泽西州北不伦瑞克，2026年4月16日（环球新闻社）-- Adlai Nortye Ltd.（纳斯达克：ANL）（“公司”或“Adlai Nortye”），一家专注于开发创新癌症疗法的临床阶段生物技术公司，今天宣布已达成一项证券购买协议，进行私人投资公开股权融资，预计在扣除配售代理费用和其他私募费用之前，将获得约1.5亿美元的总收益。

The oversubscribed transaction includes participation from both new and existing institutional investors. New investors include Soleus Capital, Perceptive Advisors, ADAR1 Capital Management, MPM BioImpact, Octagon Capital, Eventide Asset Management and Kalehua Capital, DAFNA Capital Management, etc., with additional participation from existing investors including Cormorant Asset Management, Columbia Threadneedle Investments, Balyasny Asset Management, Casdin Capital and Squadron Capital Management, Superstring Capital Management, etc..

超额认购的交易包括新老机构投资者的参与。新投资者包括索勒斯资本、感知顾问公司、ADAR1资本管理、MPM生物影响、八角资本、Eventide资产管理、Kalehua资本、DAFNA资本管理等，现有投资者也进一步参与，包括Cormorant资产管理、哥伦比亚Threadneedle投资、Balyasny资产管理、Casdin资本和Squadron资本管理、Superstring资本管理等。

In the private placement, the Company is selling 11,320,755 ADSs, at a price of $13.25 per ADS, which equals the closing price of the Company’s ADSs on the Nasdaq Global Market on April 15, 2026. The private placement is expected to close on April 17, 2026, subject to the satisfaction of customary closing conditions..

在私募配售中，公司以每股13.25美元的价格出售11,320,755份美国存托股份（ADS），该价格等于公司于2026年4月15日在纳斯达克全球市场ADS的收盘价。此次私募预计将于2026年4月17日完成，但需满足惯例的交割条件。

Carsten Lu, Chairman and Chief Executive Officer of Adlai Nortye, said, “We are delighted to have brought together this group of high-quality healthcare investors to support Adlai Nortye and our innovative, potentially best-in-class RAS-targeting therapies. We thank our investors for their confidence in the broad potential of our RAS-targeting pipeline and our next-generation ADC payload platform, RASiCA™, as well as their commitment to our mission to transform deadly cancer into a chronic and eventually curable disease.”.

安道利北拓医药董事长兼首席执行官吕卡斯滕表示：“我们很高兴能够汇集这批高质量的医疗投资者来支持安道利北拓医药及我们创新的、潜在同类最优的RAS靶向疗法。我们感谢投资者对我们RAS靶向研发管线以及下一代ADC载荷平台RASiCA™广阔潜力的信任，并且认同我们将致命癌症转化为慢性病并最终可治愈疾病的使命。”

Leerink Partners, Cantor, Lucid Capital Markets, H.C. Wainwright & Co. and Jones are acting as joint placement agents for the private placement.

Leerink Partners、Cantor、Lucid Capital Markets、H.C. Wainwright & Co. 和 Jones 担任此次私募的联合配售代理。

The securities being issued and sold in this private placement have not been registered under the Securities Act of 1933, as amended, or applicable state securities laws, and may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements.

本次私募发行和出售的证券尚未根据修订后的《1933年证券法》或适用的州证券法进行注册，且除非依据有效的注册声明或适用的注册要求豁免，不得在美国境内发售或出售。

Adlai Nortye has agreed to file a registration statement with the Securities and Exchange Commission registering the resale of the ADSs issued in the private placement..

阿德莱·诺特公司已同意向证券交易委员会提交一份登记声明，登记在私募中发行的美国存托股份的转售。

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction..

本新闻稿不构成出售或征求购买本文所述任何证券的要约，也不得在任何州或司法管辖区出售这些证券，如果在该州或司法管辖区进行此类要约、征求或出售属于违法，则在根据任何此类州或司法管辖区的证券法进行注册或资格认证之前，不得进行此类要约、征求或出售。

About

关于

Adlai Nortye

阿德莱·诺泰

Adlai Nortye (Nasdaq: ANL) is a global clinical-stage company at the forefront of discovering and developing innovative cancer therapies. Leveraging its dual R&D presence in the United States and China, Adlai Nortye is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a significant difference.

Adlai Nortye（纳斯达克：ANL）是一家全球临床阶段公司，处于发现和开发创新癌症疗法的前沿。凭借其在美国和中国的双重研发优势，Adlai Nortye 正在构建一个强大的候选药物管线，专注于其认为能够产生重大影响的两个关键领域。

(1) RAS-targeting therapies: Adlai Nortye is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to the tumor. (2) Next-generation cancer immunotherapies: Adlai Nortye’s drug candidates, AN8025 (a tri-functional fusion protein of αPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways..

(1) 针对RAS的疗法：Adlai Nortye公司正在通过AN9025（一种口服的泛RAS(ON)抑制剂）和AN4035（一种靶向CEACAM5的ADC，将强效的泛RAS(ON)抑制剂直接递送至肿瘤）来应对RAS驱动的癌症。(2) 下一代癌症免疫疗法：Adlai Nortye公司的候选药物AN8025（一种三功能融合蛋白αPD-L1 x CD86变体 x LAG3变体），作为T细胞和抗原呈递细胞调节剂，以及AN4005（一种首创的口服小分子PD-L1抑制剂），旨在以新颖的方式激活癌症免疫。

Cautionary Note Regarding Forward-Looking Statements

关于前瞻性陈述的谨慎声明

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “design,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “positioned,” “potential,” “predict,” “seek,” “should,” “target,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology.

本新闻稿包含经修订的《1933年证券法》第27A条和经修订的《1934年证券交易法》第21E条所指的前瞻性陈述。在某些情况下，您可以通过诸如“目标”、“预期”、“假设”、“相信”、“考虑”、“继续”、“可能”、“设计”、“由于”、“估计”、“期望”、“目的”、“打算”、“可能”、“目标”、“计划”、“定位”、“潜力”、“预测”、“寻求”、“应该”、“针对”、“将”、“会”等术语以及表明未来事件或趋势的其他类似表述，或这些术语的否定形式或其他类似措辞来识别前瞻性陈述。

All statements other than statements of historical facts contained in this press release are forward-looking statements. These forward-looking statements include, but are not limited to, statements about: the expected closing date of the private placement; cash operating runway; and the intended use of proceeds.

本新闻稿中包含的所有陈述，除历史事实陈述外，均为前瞻性陈述。这些前瞻性陈述包括但不限于以下内容的陈述：私募预计完成日期；现金运营跑道；以及所得款项的预期用途。

These and other risks are described in greater detail under the section titled “Risk Factors” contained in the company’s Annual Report on Form 20-F and earnings release on Form 6-K and the Company’s other filings with the SEC. Any forward-looking statements that the Company makes in this press release are made pursuant to the Private Securities Litigation Reform Act of 1995, as amended, and speak only as of the date of this press release.

这些风险及其他风险在公司年度报告 Form 20-F 中标题为“风险因素”的部分、Form 6-K 上的收益发布以及公司向美国证券交易委员会提交的其他文件中有更详细的描述。公司在本新闻稿中做出的任何前瞻性声明均依据修订后的《1995年私人证券诉讼改革法案》发布，且仅截至本新闻稿发布之日有效。

Except as required by law, the company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise..

除非法律要求，公司不承担公开更新任何前瞻性陈述的义务，无论是由于新信息、未来事件或其他原因。

Company contact:

公司联系人：

Investor Relations

投资者关系

Email: ir@adlainortye.com

电子邮件：ir@adlainortye.com